Differential distribution of tumor‑associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors

Zhu,Qinyi; Wu,Xiaoli; Wang,Xipeng

doi:10.3892/ol.2016.5428

Differential distribution of tumor‑associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors

Authors:
- Qinyi Zhu
- Xiaoli Wu
- Xipeng Wang
View Affiliations

Affiliations: Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, P.R. China
Published online on: November 23, 2016 https://doi.org/10.3892/ol.2016.5428
Pages: 159-166
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial ovarian cancer (EOC) is one of the predominant causes of cancer-associated mortality in women with gynecological oncology. Tumor‑associated macrophages (TAMs), regulatory T cells (Treg cells) and T helper cell 17 (Th17) cells have been hypothesized to be involved in the progression of EOC. However, the association between TAMs and T cells remains to be elucidated. The aim of the present study was to investigate the differential distribution of TAMs, Treg cells and Th17 cells in benign ovarian tumor tissues and in tissues from patients with EOC, and to examine their association with the clinical pathology of EOC. A total of 126 tissue samples from patients with EOC and 26 tissue samples from patients with benign ovarian tumors were analyzed, and it was identified that the distribution of TAMs, Treg cells, Th17 cells and the ratio of Treg/Th17 cells were higher in the patients with EOC using triple color immunofluorescence confocal microscopy. The high frequency of TAMs and ratio of Treg/Th17 cells in late tumor grades suggested that they may be significant in tumor progression. The frequency of TAMs was different between the histological types of EOC. Immunohistochemistry was used to investigate the microvessel density (MVD) in the EOC and benign ovarian tumor tissues. A higher MVD was observed in the EOC patient tissues, particularly, in the late tumor grade tissues. The present study provided clinical data demonstrating the high distribution of TAMs and T‑cells in EOC, which may contribute to tumor progression through angiogenesis. The mechanisms by which TAMs are associated with Treg cells and Th17 cells requires further investigation as prognostic factors and therapeutic targets for EOC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Yap TA, Carden CP and Kaye SB: Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer. 9:167–181. 2009. View Article : Google Scholar : PubMed/NCBI
3	Dunn GP, Old LJ and Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
4	Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA and Swisher EM: Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 109:215–219. 2008. View Article : Google Scholar : PubMed/NCBI
5	Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH and Nelson BH: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PloS One. 4:e64122009. View Article : Google Scholar : PubMed/NCBI
6	Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA and Coukos G: Intraepithelial T cells and tumor proliferation: Impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 115:2891–2902. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G and Zou W: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67:8900–8905. 2007. View Article : Google Scholar : PubMed/NCBI
8	Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al: Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 107:7875–7880. 2010. View Article : Google Scholar : PubMed/NCBI
9	Witz IP: The tumor microenvironment: The making of a paradigm. Cancer Microenviron 2 Suppl. 1:9–17. 2009. View Article : Google Scholar
10	Allavena P, Sica A, Solinas G, Porta C and Mantovani A: The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit Rev Oncol Hematol. 66:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I and Ben-Baruch A: The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res. 12:4474–4480. 2006. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Deavers M, Patenia R, Bassett RL Jr, Mueller P, Ma Q, Wang E and Freedman RS: Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. J Transl Med. 4:302006. View Article : Google Scholar : PubMed/NCBI
13	Mantovani A and Allavena P: The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 212:435–445. 2015. View Article : Google Scholar : PubMed/NCBI
14	Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol. 4:330–336. 2003. View Article : Google Scholar : PubMed/NCBI
15	Ouyang W, Kolls JK and Zheng Y: The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 28:454–467. 2008. View Article : Google Scholar : PubMed/NCBI
16	Chen Z, Ding J, Pang N, Du R, Meng W, Zhu Y, Zhang Y, Ma C and Ding Y: The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol. 8:612013. View Article : Google Scholar : PubMed/NCBI
17	Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, et al: Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res. 2:332–340. 2014. View Article : Google Scholar : PubMed/NCBI
18	Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q and Wang H, Chen J and Wang H: Tumor-associated macrophages recruit CCR6⁺ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PloS One. 6:e194952011. View Article : Google Scholar : PubMed/NCBI
19	Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
20	Xiaodan Meng, Volkmar Müller, Karin Milde-Langosch, Fabian Trillsch, Klaus Pantel and Heidi Schwarzenbach: Circulating cell-free mir-373, mir-200a, mir-200b and mir-200c in patients with epithelial ovarian cancer. Adv Exp Med Biol. 924:3–8. 2016. View Article : Google Scholar : PubMed/NCBI
21	Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F and McGuire WP: Gynecologic Oncology Group Study: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 25:3621–3627. 2007. View Article : Google Scholar : PubMed/NCBI
22	Colvin EK: Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 4:1372014. View Article : Google Scholar : PubMed/NCBI
23	Salvi S, Segalla F, Rao S, Arienti F, Sartori M, Bratina G, Caronni E, Anichini A, Clemente C, Parmiani G, et al: Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res. 55:3374–3379. 1995.PubMed/NCBI
24	Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. 2004. View Article : Google Scholar : PubMed/NCBI
25	Barnett B, Kryczek I, Cheng P, Zou W and Curiel TJ: Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am J Reprod Immunol. 54:369–377. 2005. View Article : Google Scholar : PubMed/NCBI
26	Dietl J, Engel JB and Wischhusen J: The role of regulatory T cells in ovarian cancer. Int J Gynecol Cancer. 17:764–770. 2007. View Article : Google Scholar : PubMed/NCBI
27	Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszewska I, Kaszewski W, Michalkiewicz J and Zegarski W: Collaborating with the enemy: Function of macrophages in the development of neoplastic disease. Mediators Inflamm. 2013:8313872013. View Article : Google Scholar : PubMed/NCBI
28	Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, Shibata K, Ohta M, Kitano S and Mori M: Prognostic value of tumor-infiltrating FOXP3⁺ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol. 34:173–179. 2008. View Article : Google Scholar : PubMed/NCBI
29	Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S and Odunsi K: Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. Cancer Immun. 13:12013.PubMed/NCBI
30	Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:18538–18543. 2005. View Article : Google Scholar : PubMed/NCBI
31	Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG and Daemen T: Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 61:7305–7309. 2001.PubMed/NCBI
32	Kawamura K, Komohara Y, Takaishi K, Katabuchi H and Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int. 59:300–305. 2009. View Article : Google Scholar : PubMed/NCBI
33	Pittet MJ: Behavior of immune players in the tumor microenvironment. Curr Opin Oncol. 21:53–59. 2009. View Article : Google Scholar : PubMed/NCBI
34	Zamarron BF and Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
35	Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T and Nijman HW: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 58:449–459. 2009. View Article : Google Scholar : PubMed/NCBI
36	Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, et al: Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 129:1016–1025. 2009. View Article : Google Scholar : PubMed/NCBI
37	Shieh YS, Hung YJ, Hsieh CB, Chen JS, Chou KC and Liu SY: Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 16:751–760. 2009. View Article : Google Scholar : PubMed/NCBI
38	Toge H, Inagaki T, Kojimoto Y, Shinka T and Hara I: Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages. Int J Urol. 16:801–807. 2009. View Article : Google Scholar : PubMed/NCBI
39	Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol. 109:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
40	Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Porembka MR, Herndon JM, Eberlein TJ, Goedegebuure P and Linehan DC: Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol. 185:4063–4071. 2010. View Article : Google Scholar : PubMed/NCBI
41	Hou F, Li Z, Ma D, Zhang W, Zhang Y, Zhang T, Kong B and Cui B: Distribution of Th17 cells and Foxp3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer. Clin Chim Acta. 413:1848–1854. 2012. View Article : Google Scholar : PubMed/NCBI